Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery
Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery
复制标题
DOI：
10.1016/j.bcp.2016.09.014
复制
发表时间：
2017-03-01
影响因子：
5.8
通讯作者：
Jochmans, Dirk
中科院分区：
文献类型：
--
作者：
Heylen, Elisabeth;Neyts, Johan;Jochmans, Dirk
开发预防或治疗呼吸道合胞病毒（RSV）感染的抗病毒策略非常重要，特别是考虑到RSV是儿科呼吸道感染的最重要原因之一。然而，尽管付出了巨大的努力，但没有抗病毒药物或疫苗被批准用于预防或治疗RSV感染。在过去的十年中，已经发现了几种靶向不同RSV蛋白的抑制剂。在这里，我们回顾了最重要的化学系列以及最近的事态发展，了解哪些病毒蛋白质和/或宿主细胞因子是抑制病毒复制的良好目标。此外，我们强调目前在体外和体内模型系统的疾病。许多分子目前处于（高级）临床前或临床开发中。预计在未来几年内，这一领域将取得重大突破。(C)2016年6月，作者。爱思唯尔公司出版
The development of antiviral strategies to prevent or treat respiratory syncytial virus (RSV) infections is of great importance, especially considering the fact that RSV is one of the most important causes of pediatric respiratory infections. However, despite intense efforts, there is no antiviral or vaccine approved for the prevention or treatment of RSV infections. Several inhibitors, targeting different RSV proteins have been discovered over the past decade. We here review the most important chemical series as well as recent developments in understanding which viral proteins and/or host cell factors are good targets for inhibition of viral replication. In addition, we highlight the current in vitro and in vivo model systems of the disease. A number of molecules are currently in (advanced) preclinical or clinical development. Significant breakthroughs in the field may be expected in the upcoming years. (C) 2016 The Authors. Published by Elsevier Inc.